Catheter-Based Radiofrequency Renal Denervation: Location Effects on Renal Norepinephrine
- PMID: 25576624
- PMCID: PMC4804121
- DOI: 10.1093/ajh/hpu258
Catheter-Based Radiofrequency Renal Denervation: Location Effects on Renal Norepinephrine
Abstract
Background: Clinical studies indicate that blood pressure (BP)-lowering effects of radiofrequency (RF) renal denervation (RD) are sustained for up to 2 years, although a recent clinical trial failed to find a major effect compared to sham treatment. In most previous studies, the efficacy of RD has not been assessed. The current study determined whether RD in different regions of the renal artery causes different degrees of RD as assessed with renal norepinephrine (NE) levels.
Methods and results: Unilateral RD was performed on 14 pigs divided into 3 groups: RD near the ostium, in the main renal artery near the bifurcation, and in extrarenal branches of the renal artery. After 2 weeks post-RD, the pigs were euthanized, renal cortex tissue was collected for NE measurement, and renal arteries were prepared for histological analysis. Renal NE decreased by 12% with RD at the ostium, 45% with RD near the bifurcation in the main renal artery, and 74% when RD was performed in extrarenal artery branches. The number of renal nerves was greatest in extrarenal branches and in the main artery compared to the ostium and the average distance from the lumen was greatest for nerves at the ostium and least at the branches.
Conclusions: RF RD lowers renal NE more significantly when performed in branches of the renal artery closer to the kidney. Increased efficacy of RF RD in extrarenal arterial branches may be due to the greater number of nerves in close proximity to the artery lumen in the branches.
Keywords: blood pressure; hypertension; norepinephrine; radiofrequency ablation; renal denervation; renal nerves..
© American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Figures







References
-
- Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, T. Meredith IT, Malaiapan Y, Worthley MI, Worthley SG. Catheter-based renal denervation for resistant hypertension 12-month results of the EnligHTN I First-in-Human Study using a multielectrode ablation system. Hypertension 2014; 64:565–572. - PubMed
-
- Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393–1401. - PubMed
-
- Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275–1281. - PubMed
-
- Esler M, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376:1903–1909. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous